ArticleFrontiers in immunology2026

Correction: Efficacy and safety of BCMA-or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies.

Jiashun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.